Criteria Capital Risc (formerly Caixa Capital Risc, rebranded July 2026) is the venture capital management company of CriteriaCaixa, the holding company of Fundación Bancaria "la Caixa". It deploys through two specialised vehicles: Criteria Venture Tech, focused on deep tech with verticals in artificial intelligence, cybersecurity, and software and data infrastructure; and Criteria Bio Ventures, specialised in biotechnology and health. Criteria Venture Tech invests from pre-seed and seed with an explicit strategy of taking lead or co-lead positions, retaining capacity to back its best performers into growth rounds. Criteria Bio Ventures backs therapeutics companies from early stage through growth, having been first and principal investor in Minoryx Therapeutics and Adaptam Therapeutics. Under the 2030 Strategic Plan it targets €300M of investment volume, focused primarily on Spain and Portugal and selectively on the rest of Europe and North America. Differentiation comes from permanent holding-company balance-sheet capital, board-level active management of its holdings, and over 20 years as one of Iberia's reference venture investors.